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Abstract 
To understand multifactorial conditions such as Alzheimer’s disease (AD) we need brain signatures that 
predict the impact of multiple pathologies and their interactions. To help uncover the relationships between 
pathology affected brain circuits and cognitive markers we have used mouse models that represent, at least in 
part, the complex interactions altered in AD, while being raised in uniform environments and with known genotype 
alterations. In particular, we aimed to understand the relationship between vulnerable brain circuits and memory 
deficits measured in the Morris water maze, and we tested several predictive modeling approaches. We used in 
vivo manganese enhanced MRI traditional voxel based analyses to reveal regional differences in volume 
(morphometry), signal intensity (activity), and magnetic susceptibility (iron deposition, demyelination). These 
regions included the hippocampus, olfactory areas, entorhinal cortex and cerebellum. The properties of these 
regions, extracted from each of the imaging markers, were used to predict spatial memory. We next used 
eigenanatomy, which reduces dimensionality to produce sets of regions that explain the variance in the data. 
For each imaging marker, eigenanatomy revealed networks underpinning a range of cognitive functions including 
memory, motor function, and associative learning, allowing the detection of associations between context, 
location, and responses. Finally, the integration of multivariate markers in a supervised sparse canonical 
correlation approach outperformed single predictor models and had significant correlates to spatial memory. 
Among a priori selected regions, expected to play a role in memory dysfunction, the fornix also provided good 
predictors, raising the possibility of investigating how disease propagation within brain networks leads to 
cognitive deterioration. Our cross-sectional results support that modeling approaches integrating multivariate 
imaging markers provide sensitive predictors of AD-like behaviors. Such strategies for mapping brain circuits 
responsible for behaviors may help in the future predict disease progression, or response to interventions.
Keywords: Alzheimer's Disease, Behavior, Magnetic Resonance Imaging, Memory, Mouse Models, 
Multivariate Analysis, Predictive Modeling, Biomarkers
11. Introduction
A key question in Alzheimer’s disease (AD) research is how pathology differentially and sequentially affects 
vulnerable brain circuits, thereby giving rise to behavioral changes. Although critically important, detailed 
descriptions of interactions between genes and structural and functional phenotypes are poorly described.  
However, these interactions dictate the vulnerability for cognitive dysfunction in the context of aging and AD 
related pathologies. Investigating the circuits and mechanisms underlying cognitive dysfunction is important for 
understanding what triggers the switch from normal aging to AD, what predicts rates of disease progression, and 
how patient-specific therapeutic strategies may be developed [1]. Therapies for neurodegeneration have been 
directed to individual targets, such as altered synaptic transmission, amyloid deposition, or abnormal tau 
phosphorylation - all well-demonstrated pathologies in AD [2] [3]. Additional factors, such as cardio vascular 
status [4] [5], insulin resistance [6], and diabetes [7] may also influence cognition [4]. Importantly, neuro-
immunological mechanisms, interacting with systemic inflammatory mediators and obesity, are thought to also 
modulate AD pathology [5, 8, 9]. Since attacking AD pathologies separately has not yet provided effective 
strategies for prevention or reduction of cognitive damage, we need models that provide an integrated view of 
how multiple variables and risk factors contribute to system wide dysfunction. We currently lack the quantitative 
integrative models required to understand this multifactorial condition.
To help understand the causative links between the biological and cognitive substrates typical of AD, it is 
helpful to conceptualize the brain as a set of interacting regions forming a spatially distributed network [10]. 
Structural networks integrate effects from changes occurring at different scales (synapse, cells, circuits), which 
in turn modulate the properties of functional networks. Several large-scale networks have been mapped in the 
brain and characterized by distinct functional profiles, such as sensory perception, movement, attention and 
cognition [11] [12]. However, it is not well understood how brain sub-networks map to the cognitive domain. 
Understanding these relationships in the normal brain, and their alterations in disease may inform on the 
mechanisms underlying mild cognitive impairment (MCI) or dementias such as AD [13]. 
One strategy to help understand how circuits influence behavior is to link imaging to the clinical AD cognitive 
phenotypes. The progressive loss of cognitive memory is commonly diagnosed using tests such as the Mini–
Mental State Examination (MMSE) [14], the Montreal Cognitive Assessment [15], and others [16]. Clinical 
2populations of individuals diagnosed with AD have shown overlaps in the patterns of gray matter atrophy [17], 
Aß distribution [18], and axonal density changes [19] [19], but there are also marked differences in brain atrophy 
[20] or tau pathology distribution [21]. Such differences may relate to population heterogeneity in terms of 
genetics, disease stage, or comorbidities. An alternative hypothesis to explore AD etiology is based on selective 
vulnerability of cells and axonal pathways favoring disease propagation. Imaging can provide in vivo biomarkers 
[22] [23] that are related to pathology as observed ex vivo, or to functional changes. To successfully link imaging 
to clinical phenotypes, we need to develop integrative models that explain the initiation, potentiation, and 
propagation of selective vulnerability in cells and networks that underlie AD processes, in relation to risk factors.
Neuroimaging approaches to map brain levels of behavioral descriptors have traditionally used voxel based 
statistical analyses (VBA) of deformation fields, structural and functional connectivity maps, vascular perfusion, 
or amyloid deposition and tau maps. But statistical approaches that pursue a dichotomous strategy, and aim to 
separate data according to image features do not necessarily explain the behavioral changes, nor do they 
disclose the biological processes underlying them. More recently predictive modeling approaches have been 
proposed to provide statistically relevant imaging correlates of memory changes spanning a continuum range, 
as observed in AD [24] [25] [26]. 
In this study, we have used mouse models for AD to develop such predictive approaches. Mice provide tools 
for dissecting the contributions of genes on circuits and behavior. In particular, they provide homogenous 
populations, and can be tightly controlled for genetic and environmental factors, thus simplifying the problem of 
mapping brain circuits responsible for behavior. To establish and test a novel integrative predictive modeling 
approach we have used the APPSwDI+/+/mNos2-/- (CVN-AD) strain. This mouse provides an AD-like pathological 
background required for studying the underlying mechanisms of regional vulnerability. CVN-AD mice replicate 
multiple AD pathologies, including amyloid and tau deposition, neuronal loss, altered microglial activity with 
typical AD-like inflammatory patterns and deficits in memory and learning [27] [28] [29] [30] [31]. The appearance 
of cognitive deficits with aging in this strain mimics processes in humans with AD and can be assessed using 
the Morris water maze test. This behavioral test is commonly used to quantify the loss of spatial learning and 
memory in animal models of aging and AD [32, 33].
To map behavioral changes to specific brain regions and networks we have used manganese enhanced in 
vivo MRI. Manganese ions (Mn2+) are paramagnetic and induce T1 shortening [34], enhancing tissue contrast 
3[35]. Mn2+ has also been used to characterize trans-synaptic connectivity and axonal transport properties in 
rodents [36, 37] [38]. Importantly, Mn2+  enters neural cells via voltage gated calcium channels and vesicular 
reuptake, presenting an alternative for task based fMRI in rodents [39] [40], while alleviating limitations due to 
the types of tasks that animals can perform in the magnet, or to anesthesia [41]. These strategies to characterize 
brain structure and function in CVN-AD mice in relation to age matched controls can identify vulnerable brain 
circuits responsible for behaviors typical of AD. 
To identify vulnerable regions and networks that predict deficits in memory and learning, we used an 
integrative approach that was not linked to a single identified neuropathological mechanism, but was reflective 
of multiple concomitant factors. We evaluated how traditional mass-univariate analyses can predict behavior 
dysfunction, and followed with a multivariate approach involving dimensionality reduction. Eigenanatomy, a 
sparse dimensionality reduction method, was incorporated to extract brain regions responsible for changes in 
morphometry, signal intensity due to Mn2+ uptake (reflective of brain activity), and magnetic susceptibility 
(reflective of altered iron homeostasis and conducive to oxidative stress and inflammation) [42] [43]. However, 
these methods analyzed individual biomarkers separately. We have employed both a data-driven as well as a 
hypothesis-driven approach to associate imaging phenotypes with behavioral markers for cognitive status and 
to identify circuits vulnerable to AD like pathology. Eigenanatomy produced candidate regions and circuits, and 
we selected regions that appeared important based on one or more biomarkers, and confirmed as relevant to 
AD from previous studies. To predict cognitive dysfunction based on in vivo multivariate imaging markers we 
used sparse canonical correlation analysis (SCCA) [44, 45]. SCCA selects regions so to maximize correlation 
among imaging and cognitive measures, in a supervised approach. The result is a network of regions that 
underlie changes in cognition, incorporated in a multivariate analysis. Our results provide insight into the 
relationships between structural networks and cognitive function in animal models of AD, supporting the value 
of multivariate approaches for humans with AD.
2. Materials and Methods
To test the hypothesis that we can identify vulnerable brain circuits involved in behaviors where aged mouse 
models for Alzheimer’s disease (AD) differ relative to their age matched controls, we used in vivo multivariate 
4magnetic resonance imaging (MRI) and the Morris Water Maze test for spatial memory. Our strategy examined 
each biomarker at a time, as well as an integrative predictive modeling framework.
2.1 Animals
The study was conducted under protocols approved by the Duke IACUC. CVN-AD (APPSwDI/mNos2-/-) (11 
mice) and mNos2-/- controls (13 mice), aged 75  4.4 weeks were handled and acclimated to water for 5 days. .9 ±
Mice were then implanted with Alzet 1007D minipumps (Durect Corp, Cupertino, CA), containing 100 µl of 64 
µm/µl MnCl2*4(H2O) (Sigma Aldrich, St Louis, MO), in 100 mmol bicine (Sigma-Aldrich, St Louis, MO). Animals 
were acclimated for 3 days following pump implantation, before behavioral testing. A summary of the 
experimental design is shown in Fig. 1. 
2.2 Behavioral Testing 
To test spatial memory which declines in AD, we used the hidden platform Morris Water Maze. For 5 days, 
mice received 4 trials a day (of maximum 60 s each), in trial pairs (60 s between trials) separated by 60 min 
intervals. Probe trials were run 60 minutes after the last trial on days 3 and 5. Swim time and distance were 
measured using Ethovision (Noldus Information Technology, Blacksburg, VA). Statistical analysis used SPSS 
(IBM, Armonk, NY), and included a repeated measure ANOVA, followed by Bonferroni corrected posthoc tests. 
A p-value < 0.05 was considered significant.
2.3 Imaging 
In vivo imaging was done using a 7 T, 20-cm bore Bruker BioSpec 70/20 magnet (Bruker Biospin, Ettlingen 
GE/USR, Billerica, MA), interfaced to an Avance III console. The scanner has actively shielded gradients with 
integrated shims. The 198/114 mm outer/inner diameter insert gradient coil can supply 440 mT/m, at a rigif and 
rise time of 110 μs. We used a quadrature radio frequency transmit-receive cryogenic coil.
Two protocols were used to image the mouse brain at 100 µm resolution. To quantify morphometric changes 
and manganese uptake we used a T1-weighted RARE sequence with FOV 2x2x1 cm, matrix 200x200x100, 
NEX=2, BW=100 kHz, min TE=10.3 ms, TEeff=20.6 ms, TR=150 ms, echo spacing 10.3 ms, RARE partitions 4, 
5acquired in 23 min. To estimate quantitative susceptibility maps we used a multi echo GRE with FOV 
1.92x1.92x0.9; matrix 192x192x90, 8 echoes with spacing of 5.5 ms, NEX=1, TE1=3.9 ms; TR=100 ms, flip=30°, 
BW=62.5KHZ, respiratory gated, acquired in ~30-40 mins. 
To ensure reproducible positioning, mice were restrained in a cradle equipped with ear bars, and a nose 
cone for isoflurane delivery (1.5±1%). Animals were monitored throughout the experiment, temperature and 
respiratory rate being maintained at physiological levels (37oC, 70-110 /min) by circulating warm water under the 
cradle, and adjusting the anesthesia level.
2.4 Image Preprocessing
Images were bias field corrected [46], skull stripped [47], and the resulting brain masks were manually 
edited. All brain images were rigidly aligned into the Waxholm space [48], and averaged to create a minimum 
deformation template [49] [50]. The template was labeled with a set of 332 regions, symmetric for the left and 
right hemispheres [51], defined on a single mouse brain [52]. To estimate morphometric differences, we used 
the log-transformed Jacobian determinants of the deformation fields (logJAC), mapping individual brains to the 
average. This enables comparisons with a symmetric distribution, with the same prior probability for shrinkage 
or expansion [53]. We used the T1-weighted images, where the voxel intensity reflects Mn2+ uptake, which 
happens at least partly through calcium channels, to provide estimates of neuronal activity independently of 
hemodynamic activity [54]. Average T1-weighted image values for each mouse brain were normalized to a 
reference brain value. We calculated quantitative susceptibility maps (QSM) sensitive to iron, amyloid 
accumulation, and myelin using STI Suite [55]. Susceptibility values were directly used for comparison without 
referencing to any selected region of interest, which essentially sets the susceptibility reference to the mean 
susceptibility of the whole structure within the FOV. STI Suite uses a Laplacian-based method to unwrap the 
phase, after which the background is eliminated using vSHARP (Wu et al., 2012). The corrected phase images 
were combined, weighting the two channels. We used a two-step streaking artifact reduction regularized 
reconstruction (STAR-QSM) [56], which optimally weighs data consistency and smoothness for both high and 
low susceptibility variations. 
2.5 Voxel Based Analysis
6All three contrast images (log Jacobian, normalized T1-weighted RARE, and QSM) were mapped into the 
space of the minimum deformation template, and smoothed with a 200 μm kernel.  This kernel was selected to 
highlight the scale of features at which we expect to detect pathology-related differences across these MRI-
based measurements. SPM [57] was used with voxel-wise false discovery rate correction. 
2.6 Eigenanatomy
We hypothesized that eigenanatomy [25], a sparse dimensionality reduction technique, will confer increased 
power to detect differences between genotypes. The method approximates an eigen decomposition of an image 
set with spatial basis functions (eigenanatomy vectors) that are unsigned, sparse, and anatomically clustered. 
We employed the eigenanatomy vectors as anatomical and functional imaging predictors. We leveraged the 
technique in two stages: first, to reduce the dimensionality in an unsupervised setting; second, to perform a 
supervised regression within the setting of cross-validation.
The goal of eigenanatomy is to identify sparse functions which approximate the eigenvectors (𝑣𝑝 = 𝑋𝑇𝑣𝑛 𝑎𝑛𝑑 
of the n x p image matrix X, where each row n represents the data for one subject, and has p entries 𝑣𝑛 = 𝑋𝑣𝑝) 
(voxel values). The method approximates X with i sparse singular vectors , treating the positive and 𝑣𝑠𝑝  𝑖 (𝑣𝑠𝑝 +   𝑖 ) 
negative components (  separately, and imposes positivity constraints on both:𝑣𝑠𝑝 ‒   𝑖 )
subj. to  (Eq.1)𝑎𝑟𝑔𝑚𝑖𝑛
𝑣𝑠𝑝 +   𝑖 , 𝑣𝑠𝑝 ‒   𝑖 ‖𝑋𝑇𝑋𝑣𝑠𝑝 +   𝑖 ‒ 𝑣𝑝 +   𝑖 ‖2 + ‖𝑋𝑇𝑋𝑣𝑠𝑝 ‒   𝑖 ‒ 𝑣𝑝 ‒   𝑖 ‖2; ‖𝑣𝑠𝑝 +   𝑖 ‖1 = ‖𝑣𝑠𝑝 ‒   𝑖 ‖1 = 𝛾
where  is the sparseness parameter. The weight on the L1 penalty is set to reach the desired sparseness 𝛾
and guarantees that only a subset of voxels is considered [44] [58]. The minimization uses a nonlinear conjugate 
gradient, with sparseness imposed through soft thresholding S(v, ), which rejects clusters below a threshold.  𝛾
The resulting pseudo-eigenvectors are sparse, unsigned, and represent the input data (X) through weighted 
averages.
To estimate the generalization performance for our models we divided the data in training and testing groups 
(75%, and 25%), and we used a 4-fold cross-validation, as described in [59]. We assigned data to training (n=18), 
and validation (n=6) partitions in a balanced way using caret (caret.r-forge.r-project.org/), then evaluated the 
average root mean square error (RMSE) over the test partitions. Dimensionality reduction was performed using 
the function sparseDecom in ANTsR (https://github.com/ANTsX/ANTsR) for each of the imaging contrasts 
7(logJac, T1w, QSM), producing areas that have maximum covariance between subjects (Cook et al. 2014). For 
each imaging contrast we used 2 eigenvectors, a sparsity threshold of 5%, and a min cluster size of 250 voxels, 
or 6 eigenvectors for all three imaging contrasts used in the multivariate approach. These eigenregions were 
projected against the training set to generate statistical models that predict swim distance at day 4. The summary 
of the statistical models performance applied to the testing sets included the root mean square error (RMSE), 
Pearson correlation, adjusted R2 and p value (considered significant at p<0.05).  
2.7 Prior-Based Prediction Using Sparse Canonical Correlation
We used an anatomically informed, prior-based approach to constrain the solution space, to test whether 
specific brain regions were associated with cognitive performance. These regions were determined based on: 
1) eigenanatomy results, producing a supervised decomposition, and 2) anatomical priors on regions known for 
their involvement in AD, and which are recognizable in mouse models. These regions included the hippocampus, 
parasubiculum, and fornix [60] [61] (Micotti et al. 2015) (Badea et al. 2016), as well as the entorhinal and motor 
cortices. Each of these regions is likely to incur changes during training in the water maze. These regions were 
used to initialize SCCAN [58] to infer their influence on behavior. 
We hypothesized that we could identify brain networks associated with behaviors based on canonical 
correlation (CCA) [62], the multivariate extension of correlation analysis. To find the linear projections of two 
random vectors, CCA maximizes the correlation between the two linear combinations of the variables in each 
data set. Our datasets consist of imaging (X) and behavioral parameters (Y) for n subjects. The imaging 
parameter is a large  multidimensional matrix, and the behavioral parameter is ; where p is the number 𝑛𝑥𝑝 𝑛𝑥𝑞
of voxels in X for each subject, and q is the number of behavioral parameters in Y for each subject. 
Due to the greater size of the imaging matrix compared to behavior, CCA becomes ineffective. Instead 
sparse CCA has been used as a dimensionality reduction method to produce the solution vectors, x (p ×1) and 
y (q × 1), which act as weights on columns of X and Y [58]. 
(Eq.2)𝑥 ∗ , 𝑦 ∗ = 𝑎𝑟𝑔𝑚𝑎𝑥
𝑥,𝑦
𝑥𝑋𝑇 𝑌𝑦
‖𝑋𝑥‖ ‖𝑌𝑦‖ ; 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 ∑𝑗‖𝑥𝑗‖1 ≤ 𝑠,  𝑥𝑗 ≥ 0 
The x* solution vector is subjected to the “L1” norm, ||.||1, producing non-zero entries below the chosen 
sparsity threshold (Kandel et al. 2013). The gradient of the objective function in (Eq.2) is calculated with respect 
8to x and y. A nonlinear gradient descent optimizer is used to provide the solution vectors. Additionally, a cluster 
threshold and smoothness constraint are enforced to retain anatomically meaningful brain regions. As a result, 
sparse CCA produces solution vectors x* and y*, dimensioned as subsets of variables that maximize the 
correlation between imaging and behavior.
Here we focused on a single vector to represent behavioral performance, i.e. swim distance at day 4 (SD4). 
We used SCCAN to perform a sparse regression between imaging and behavior.  
𝑎𝑟𝑔𝑚𝑖𝑛
𝑥
12 ‖𝑋𝑥 ‒ 𝑦‖22 + 𝜆12 ‖𝑥‖22 + 𝜆22 ‖∇𝑥‖22 ;  𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 ‖𝑥‖1 ≤ 𝑠 (Eq.3)
where s is the desired sparseness, a ridge penalty which alleviates the problem of multicollinearity 𝜆1 
amongst regression predictor variables, and  a smoothness penalty. This is solved through a projected gradient 𝜆2
descent (Kandel et al. 2013). We note that in recent approaches the L0 penalty, which guarantees that only a 
subset of voxels is considered for the model, has been replaced with the convex approximation given by an L1 
penalty, which yields virtually identical results, in a robust approach to regression [63](Kandel et al. 2013). The 
soft thresholding operator was used to update the sparse projection of the solution vectors at each step of the 
optimization. 
We used SCCAN for a positively constrained optimization that finds projection vectors in the minimum 
deformation template space, which maximizes the relationship between image markers (separate contrasts, and 
in combination) and swim distance at day 4. The inputs for SCCAN included the training set for both imaging 
and swim distance (SD4) through the function sparseDecom2 (Dhillon et al. 2014). 
Both the imaging and behavioral data were split into training and testing sets in a ratio of 75:25, which 
allowed for 18 variables/subjects for training and 6 for testing. We chose the swim distance on day 4 (SD4) as 
the behavior to be predicted based on its robust ability to separate the groups. The sparse canonical correlation 
was initialized from each of the a priori selected image regions (1 eigenvector), using a medium prior (0.5). We 
used sparseDecom2 with 5% sparseness, 250 voxels cluster threshold, 15 iterations. No sparsity constraints 
were enforced on behavior. The projection vectors obtained from the training set model the relationship with 
behavior. These models were then used to predict swim distance for the testing set. To assess the quality of the 
predictive modelling approach we determined the relationship between the predicted and measured SD4. 
9We examined how the solution vectors from sparse CCA of different imaging contrasts performed as 
predictors on unseen behavioral data. We aimed to identify brain regions with a reliable association between 
each imaging marker and behavior using sparseDecom2, with a sparseness value that selects a small, 
informative subset of voxels (250 voxels, and 5% sparsity). Finally, the resulting eigenregions were used to fit a 
linear model to SD4. 
We tested several models to predict behavior based on imaging biomarkers using a 4-fold cross validation 
scheme. First, we examined how the clusters surviving FDR correction in the voxel based analyses (VBA) in the 
three different imaging contrasts performed as predictors for behavioral data. We compared the performance of 
these models with those generated from the sparse decomposition (SD) for each of the imaging contrasts. 
Finally, we fused the information from all imaging contrasts in a behavior supervised sparse decomposition that 
maximized the canonical correlation between imaging and swim distance. This approach was used in a 
hypothesis generating mode throughout the whole brain to identify brain circuits responsible for AD like cognitive 
decline, as well as to test our hypotheses for regions expected to be involved in memory or motor function.
All prediction methods were executed using R (www.r-project.org) and the ANTsR package 
(http://stnava.github.io/ANTsR/). The compute times required for each fold in our optimization experiments 
ranged from 2 minutes (for 2 vectors, 5% sparsity) up to 2 hours and 22 minutes (for 50 eigenvectors, 5% 
sparsity), using a MacPro equipped with 12 core 2.7 GHz Xeon E3 processors, running 10.13.6 Mac OS Sierra. 
FSLEyes (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLeyes) was used for visualization of statistical parametric 
maps overlaid on the average T1W MEMRI template generated from mNos2-/-  controls. 
3. Results
To help uncover the relationship between cognition and the biological substrates underlying Alzheimer’s 
disease (AD), experiments were carried out using a well-characterized mouse model of AD, to reduce genetic 
and environmental diversity. Behavior and imaging data were subjected to univariate and multivariate analyses. 
Spatial memory was examined through acquisition performance in the Morris water maze (Fig. 2). Swim 
distance to the hidden platform declined across testing for both genotypes (Fig. 2A). Significant genotype effects 
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emerged on block trials 3-5, where swim distances decreased in the mNos2-/- control mice relative to the CVN-
AD strain (p≤0.05). Within genotype, swim distances decreased from trial 1 to trials 3-5 in mNos2-/- control mice 
(p≤0.002), whereas in CVN-AD animals this parameter only declined from trial 1 to 5 (p=0.005). A similar 
relationship was observed for swim time (Fig. 2B). Here, swim times were reduced significantly on trials 3 and 
4 for the mNos2-/- compared to CVN-AD animals (p≤0.025). Within genotype, swim times in mNos2-/- animals 
declined from trial 1 to trials 3-5 (p<0.001). By comparison, in CVN-AD mice swim time was decreased only from 
trial 1 to 5 (p=0.001).  
Analysis of learning performance on the probe trials for swim distance on days 3 and 5 of acquisition testing 
revealed that mNos2-/- control mice had already identified the northeast (NE) quadrant as the target zone, 
whereas CVN-AD mice had not made this distinction (Fig. 2C). Swim distances in CVN-AD animals on day 3 
were shorter in the NE target (p=0.026) and longer in the northwest (NW) and southwest quadrants than mNos2-/- 
controls (p≤0.018) (Fig. 2C, left).  On probe day 5, mNos2-/- animals maintained increased swim distances in the 
target quadrant, whereas in CVN-AD mice swim distances were longer in the NE and northwest than the other 
quadrants (Fig. 2C, right).  On this probe trial, the only genotype difference was in the northwest quadrant where 
CVN-AD mice swam over a longer distance than mNos2-/- controls (p=0.003).  Similar relationships were 
observed with swim time (Fig. 2D).  With the probe trial on day 3, mNos2-/-  mice swam for longer times in the 
NE target quadrant (p=0.002) and shorter times in the northwest (p=0.004) with a trend for the southwest 
(p=0.064) quadrant compared to the CVN-AD animals (Fig. 2D, left).  By day 5 probe trial, swim time remained 
augmented in the northwest quadrant for the CVN-AD mice (p=0.045) (Fig. 2D, right).  These results indicate 
that the CVN-AD mice had learned that the north quadrants contained the target, but they were unable to 
discriminate the NE from the NW quadrant. Collectively, these results demonstrate that acquisition duration in 
the Morris water maze is prolonged in CVN-AD mice, which fail to identify the NE quadrant as the target zone in 
the probe trials.  Since in the acquisition test genotype differences were most robust on trial 4 for swim distance, 
and provided a clear separation of the two genotypes, these data were used as the dependent variables for 
predictive modeling. 
To characterize CVN-AD mice relative to age matched controls we used manganese enhanced imaging 
(MEMRI). We developed two imaging protocols to characterize anatomy and memory function based on: 1) the 
log-jacobian of the deformation fields; 2) the T1-weighted signal intensity (normalized to the average value 
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determined for a reference brain) reflecting manganese accumulation; and 3) quantitative susceptibility maps 
(QSM). Representative images for one animal are shown in Fig. 3A. We constructed minimum deformation 
templates (MDT) as study specific population atlases for each of these contrasts (Fig 3. B), and derived Jacobian 
and QSM maps (Fig. 3C). All subsequent analyses were performed in the common space of the MDT. 
We sought brain networks for which changes in imaging markers explain changes in behavior. Using 
regional and voxel based analyses (VBA) we identified significant changes in volume (Jacobian of deformation 
fields), manganese accumulation (normalized T1-weighted signal intensity), and quantitative susceptibility maps 
(QSM). All image contrasts identified differences in the olfactory areas, hippocampus, entorhinal cortex, and 
cerebellum, and the volume and T1w analyses revealed a role for the retrosplenial cortex (Fig. 4).
The reductions in volume in olfactory areas, thalamus, and hippocampus were accompanied by increased 
magnetic susceptibility, and lower manganese uptake (Fig. 4 A-D). Areas of the hypothalamus, entorhinal cortex, 
hippocampus and subiculum showed decreased susceptibility. Increases in susceptibility were noted in the 
caudate putamen and red nucleus. T1w signal intensity was overall lower on CVN-AD mice, and local differences 
between genotypes were significant at FDR 0.2 in the olfactory areas, motor cortex, primary somatosensory (S1) 
cortex, hypothalamus, and hippocampus, in particular the dentate gyrus and subiculum, and cerebellum. A more 
extensive presentation of the regional results can be found in the Supplementary Tables.
Separate analyses for volume, T1w signal and QSM were conducted using the clusters with significant VBA 
differences between the two groups to model the relationship with behavior (Fig. 4 E). Volume was ranked as 
the best predictor, followed by T1w signal, then QSM. The root mean square error (RMSE) ranged from 259±57 
cm for clusters with significant atrophy, to 274±54 cm for clusters with decreased T1w signal, while the largest 
RMSE was obtained for the combined QSM clusters (290 ±51cm). Table 1 reports the performance of all tested 
methods to produce the final models based on the 4-fold cross validation (testing) RMSE, the correlation and 
variance explained by each method, and their rank in terms of predictive performance. 
We then used eigenanatomy to identify areas of the brain with maximum covariance between subjects (Cook 
et al. 2014), producing a sparse decomposition (SD) for each of the imaging contrasts. The eigen regions based 
on volume revealed a network comprised of the frontal pole, septum, medial thalamus, retrosplenial and 
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cingulate cortex, amygdala, the CA1 area of hippocampus, and fimbria. In addition, we noted the involvement of 
sensory and motor cortices, and of the caudate putamen (Fig. 5A, top row).
The T1w signal intensity-based decomposition revealed a network including olfactory areas, the cingulate 
cortex, bed nucleus of stria terminalis, substantia innominata, amygdala and hippocampus (Fig. 5B, top row). 
The QSM based decomposition revealed involvement of the olfactory areas, septum, and cingulate cortex, 
the hippocampus, bed nucleus of stria terminalis, substantia innominata. Iron rich regions were also involved 
such as the substantia nigra, caudate putamen and globus pallidus (Fig. 5C, top row). 
By adding elements of supervision through the sparse canonical correlation of imaging and behavior we 
observed additional areas relative to the networks identified before. These included the fornix, dorsal thalamic 
nuclei, as well as the ventricles for the volume based decomposition (Fig. 5A, bottom row); the medial thalamic 
nuclei for the T1W based decomposition (Fig. 5B, bottom row); white matter such as the anterior commissure 
and corpus callosum (including areas below the motor cortex and S1) for the QSM based decomposition, and 
more extensive areas on the ventral hippocampus and primary somatosensory cortex (Fig. 5C, bottom row). 
Specific brain areas (eigen regions) found to be common in the results for all three contrasts included the 
olfactory, cingulate cortex and retrosplenial cortex, hippocampus, as well as the motor cortices, and septum. The 
substantia innominata and bed nucleus of stria terminalis were common to T1w, and QSM. 
Using a supervised approach and the combined regions from volume, T1w and QSM provided the lowest 
RMSE of 233.08 ±101.78 cm, a significant correlation of 0.94, explaining 88% of the variance in the swim 
distance (Fig. 5D). The tightest confidence intervals and largest adjusted R2 were obtained using the combined 
imaging biomarkers in the supervised approach (Fig. 5E, and Table 1). 
A nonparametric Kruskal Wallis test did not reveal a significant difference for the generalization performance 
estimated based on the 4 fold cross-validation (testing RMSE) for all models (p=0.09, chi square=22.9, df=15). 
To evaluate the 16 models performance, we compared their predictions with the measured values for the swim 
distances for the full data set. The Kruskall–Wallis analyses were followed by posthoc Tukey Kramer tests to 
control for the family wise error rate. Our results (Table 2, Supplementary Figure 1) indicated that the 
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supervised multivariate approach outperformed 12 of the other models (p=6.9*10-5, chi=45.3, df=15). These 
analyses also indicated that amongst the imaging contrasts studied, volume was the best predictor for behavioral 
performance in the water maze, followed by QSM, and then T1w. 
To test whether structures about which we have previous hypotheses are predictive of behavioral 
performance in the Morris water maze, we selected regions that appeared significant in one or more of the single 
biomarker analyses. These regions play a role in spatial memory and included the hippocampal formation, 
entorhinal cortex, parasubiculum, fornix, the primary and secondary motor cortex. Fig. 6 shows the predictive 
correlation for these models. The root mean square error, and significance of the models predicting relationships 
between imaging and behavior generally improved or were similar to the best predictor when the model included 
all three factors (Table 3). However, the single region analysis underperformed relative to the whole brain 
supervised sparse decomposition (SSD or SD2) analysis, with a maximum correlation of 0.76 for the 
parasubiculum in the combined analysis (explaining 56% of the variance), and 0.73 for its volume (explaining 
51% of the variance). This suggests that our animals model a complex, network- rather than a region-based 
disease.
Our results indicate that multivariate, integrative predictive modeling approaches may outperform any single 
one imaging modality, giving us the ability to map vulnerable brain circuits responsible for cognitive changes. 
This is in particular important for a multifactorial disease like AD, where the same regions are affected by multiple 
pathologies. 
4. Discussion
Neurodegenerative conditions such as AD arise from multifactorial pathological processes. Integrative 
modeling is an important step towards better understanding this complex disease etiology, as well as predicting 
its trajectory. Recent efforts to produce models for disease progression and response to treatment have shown 
promise in AD patients, and cognitively normal people at risk for AD [64]. However, the genetic variability and 
differences in environmental conditions to which patients have been exposed make these studies difficult. Animal 
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models provide attractive tools for conceptually advancing our understanding of complex pathological processes, 
and factor to factor interactions. Moreover, animal models are required for testing therapeutic interventions. 
Hence we used a mouse model [27], previously characterized using pathology, behavior [28], and ex vivo 
diffusion tensor MRI [65], and whose development of cognitive dysfunction mimics the development of AD. 
Our results support previous findings on learning and memory deficits in mouse models of AD [66], [67, 68]. 
Such deficits have been associated with the presence of amyloid [68, 69], tau [70], altered synaptic plasticity 
[71], or to inflammation and neurodegeneration [66] [28] [30]. The impairment in the acquisition of the Morris 
water maze was evident for CVN-AD mice relative to mNos2-/- controls when both swim distance and swim time 
were analyzed. These deficiencies were verified in the probe trials where CVN-AD mice failed to discriminate 
the target quadrant from the other quadrants early in testing and from the northwest quadrant at the end of 
testing. Our results thus confirmed that CVN-AD mice were impaired in spatial memory, in agreement to previous 
publications [28] [31]. Moreover, we identified swim distance during the 4th day of trial test as a robust measure 
that allows clear differentiation of CVN-AD models from age matched mNos2-/- controls.  
To bridge between structural and functional imaging correlates, we used manganese, which modifies MRI 
signals and accumulates during behavioral training and testing. Manganese increases image contrast due to 
differential uptake by various brain areas [72], [73, 74]. We have used this property to more accurately estimate 
morphometric changes in vivo. T1 shortening occurs as a consequence to intracellular manganese uptake, upon 
neuronal excitation/depolarization. These processes are known to correlate with synaptic firing [75] [76]. Thus, 
manganese enhanced MRI (MEMRI) provided a functional mapping tool [38] [37] [40] [77], and has been 
proposed as a surrogate to fMRI, which relies on hemodynamic changes. Our use of MEMRI is equivalent to a 
spatial memory -based fMRI, with the limitation that it lacks the temporal resolution. Rather MEMRI presents a 
picture of the brain activity, after integration over the duration of the behavioral tests. Importantly, MEMRI 
bypasses the shortcomings of anesthesia on task performance and we showed that MEMRI can be used to map 
complex brain circuits involved in spatial memory.
The observed decrease in MEMRI signal after behavioral testing supports the loss of neuronal activity in 
memory circuits in old CVN-AD mice. A loss of MEMRI signal has also been demonstrated in mouse models of 
tauopathy [40, 78]. In contrast, MEMRI signal was shown to increase 24 h after MnCl2 injection in young 5xFAD 
mice [79]. This model of AD demonstrates abundant amyloid deposition generated from a high level of 
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overexpression of mutated human amyloid precursor protein [80]. In addition to the differences between mouse 
models, the differences between these studies results may be explained by two effects: 1) high neuronal activity 
was present in younger mouse models of AD, and later decreased with age, and/or 2) our study measured a 
functional effect related to maze training, specific to memory function and diminished in older models of AD. 
The T1w MEMRI images suggested decreased Mn movement into the cells in CVN-AD models, in particular 
in olfactory areas, the hippocampus, hypothalamus, motor cortex, and also the cerebellum. The lower 
manganese uptake in CVN-AD mice was accompanied by atrophy in the olfactory areas, thalamus, and 
hippocampus, and was also associated with increased magnetic susceptibility. However, a reduced brain activity 
was expected to cause susceptibility reduction. Indeed, several areas of the hippocampus, entorhinal cortex and 
parasubiculum, as well as hypothalamus had lower susceptibility values in AD models. A decrease in 
susceptibility can be attributed to reduced manganese uptake, and also to diamagnetic properties of amyloid, or 
myelin. QSM changes did however overlap with areas of volume reduction, possibly associated with cellular and 
dendritic density reduction, leading to loss of anisotropy. QSM increases were noted in the hippocampus, 
olfactory areas, and red nucleus. VBA also identified QSM increased in iron rich areas, such as the globus 
pallidus and caudate putamen. Alterations in iron metabolism or the presence of microbleeds may lead to the 
observed predominant susceptibility increases. The increased susceptibility in areas such as the caudate 
putamen (Kirsch et al., 2009) and hippocampus was associated with decreased T1w values, thus could result 
from the higher level of iron from neurofibrillary tangles, and the aggregation of iron containing amyloid plaques. 
Hippocampal QSM increase has been associated with amyloid pathology in humans, moreover it was predictive 
of faster cognitive deterioration [81].
VBA revealed that morphometric changes survived the highest stringency in thresholded statistical maps, 
relative to QSM and T1-w signal reflecting manganese uptake. Significant changes in all three parameters were 
present in olfactory areas, septum, hippocampus in specific layers and the dentate gyrus, subiculum, 
hypothalamus and cerebellum. In summary, while the exact pathology underlying the observed changes remains 
unclear, these may be attributed to atrophy associated with neurodegeneration (or conversely, increases due to 
astrogliosis), to reduced manganese uptake and myelin loss; or to amyloid and abnormal iron deposition. 
Among phenotypic differences assessed with VBA, volume ranked best for its ability to predict memory. We 
used eigenanatomy [25] to exploit the covariance in a dataset, and identify a reduced set of voxels, assembled 
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into coherent regions. We then used regression in this reduced dimensionality space to identify associations with 
spatial memory. The regularized sparse decomposition identified that the volume of the cingulate and motor 
cortex areas had good predictive value for spatial memory. Additionally, the decomposition solutions based on 
T1w signal revealed that lower activity in the limbic thalamus, in the motor, cingulate and entorhinal cortices, as 
well as in the globus pallidus, were all predictive of the behavioral performance. Some of these areas were also 
present in the decomposition solutions based on susceptibility, which emphasized the role of the olfactory, motor, 
cingulate, and hippocampal areas.
While distinct regions were associated with behavior for different imaging parameters, a number of these 
regions were common between the three contrasts, and were overlapping with areas known to be involved in 
AD. These involved a network including septum, hippocampus, cingulate, retrosplenial and motor cortices. Our 
results also suggest a role for limbic thalamic nuclei, substantia innominata and amygdala. While the 
eigenregions were more extensive than the clusters obtained from voxel based analyses, these were also likely 
to be involved in multiple behaviors, such in motor planning and execution of the task, besides spatial memory. 
Motivated by such hypotheses we have integrated multivariate imaging biomarkers into a modeling 
framework to map brain circuits that predict performance in the water maze. We selected regions identified as 
important in our previous analyses for one or more of the biomarkers, and with demonstrated involvement in AD. 
We found that gray matter regions such as hippocampal [82], parasubiculum [83], entorhinal[84], retrosplenial 
[85] and motor cortices provided good predictions for spatial memory performance. While our techniques were 
limited in resolution to 100 µm, we were able to identify the fornix volume, and QSM as predictors for spatial 
memory function. Other white matter tracts such as the anterior commissure (connecting the temporal lobe 
structures), and corpus callosum (largely responsible for interhemispheric connectivity) may need to be 
investigated in future studies. Such studies may help understand how disease propagation within brain networks 
leads to cognitive deterioration. 
Finally, we assessed the value of individual and combined imaging biomarkers in predicting spatial memory 
for whole brain based analyses, and for selected regions which appeared as eigen solutions for one or more 
imaging markers and had demonstrated roles in AD. We found that the combined supervised approach improved 
the prediction accuracy relative to single biomarkers, in agreement with [25] [26] [86]. 
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A limitation of our approach comes from the small sample size, a problem that is common to many preclinical 
studies. This restricts us to using simpler models. However, this is alleviated by the genetic similarity of mouse 
populations relative to clinical populations. While in this study we demonstrated a promising approach for 
predictive modeling in mouse models of AD, future studies would benefit from larger samples. Such studies may 
test other correlatives, and attempt to build genotype specific models. 
Possible neurotoxic effects may limit manganese studies, in particular their applicability to longitudinal 
studies in animal models, and they are certainly not amenable to human studies. To maximize contrast while 
reducing toxicity, we chose a small but continuous delivery method, via implanted mini-pumps, over a single 
injection [87].  An additional consideration when using QSM in manganese dosed models of AD is the possibility 
of compound effects, e.g. iron accumulation, which is likely to dominate in effect size, and may induce oxidative 
tissue damage [88] [89]. However, our technique produced quantitative susceptibility maps with exquisite 
contrast by exploiting the MR phase, in addition to providing morphometry and T1-weighted signal information. 
This approach holds promise as a more direct measure of functional information based on imaging [90] [91].
Since imaging biomarkers may indicate changes before overt cognitive decline [92], such approaches can 
help with early diagnosis and patient stratification. It would be interesting to include vascular biomarkers, which 
may constitute early events in fronto-temporal dementia [92] and AD [93]. Future studies may address 
predictions along a temporal scale, and give insight into the dynamics of interactions among pathological factors, 
in relation to disease propagation.
To the best of our knowledge this is the first application of sparse predictive modeling integrating multivariate 
biomarkers for structure and brain activity, to map circuits responsible for behavioral dysfunction in models of 
AD. Mapping cognition to brain circuits will increasingly rely on such multivariate statistical algorithms involving 
clustering, module detection, or other dimensionality reduction approaches, which offer increased power to 
identify signatures of neurodegenerative disease. The success of such translational approaches will allow testing 
of mechanistic hypotheses using mouse models, and help develop better models for complex diseases.
In conclusion, we show that MEMRI can provide an integrated approach for studying brain dysfunction in 
rodent models of neurological disorders. Our approach synergized information from multivariate imaging and 
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behavioral markers, allowing for observation of multifactorial biological processes and enabling future modeling 
of such factor-factor interactions, locally or as they spread over physical brain networks, to alter functional 
networks and ultimately cognition. Our results demonstrated that, compared to using information provided by 
individual biomarkers in isolation, an integrative approach can better predict cognitive outcomes, including 
memory deficits. Such multivariate approaches hold promise to help discover mechanistic links between the 
structural and functional components of brain circuits that underlie cognitive dysfunction in AD. 
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Tables and Figure Legends
Table 1. Model performance comparison based on a whole brain unbiased analysis, showing the testing 
root mean square error of the predictions (RMSE); and the whole set based Pearson correlation (corr), 
associated p value, and the explained variance (adjusted R2). 
Table 2. To evaluate the 16 models performance, we have compared predictions with the true values for the 
measured behavior parameters (measured in cm) based on the full data set. Our Kruskall–Wallis analyses were 
followed by posthoc Tukey Kramer tests to control for the family wise error rate. Our results indicate that the 
supervised multivariate approach outperforms 12 of the other models. CI: confidence interval. VBA: voxel based 
analysis; SD2: supervised sparse decomposition.
Table 3. Model performance comparison based on a ROI prior initialized based analysis, showing the testing 
root mean square error of the predictions (RMSE); and the whole set based Pearson correlation (corr), 
associated p value, and the explained variance (adjusted R2). Hc: hippocampus; PaS : parasubiculum; CEnt: 
caudal entorhinal cortex; fx: fornix; M1: primary motor cortex; M2: secondary motor cortex.
Figure 1. Experimental timeline. Each animal was implanted with a MnCl2 filled minipump on day 0 (d0), 
then acclimated for 3 days. Behavior was assessed over 5 days (d3-d7) using the Morris Water Maze (MWM). 
Subsequently mice were imaged using in vivo MRI.
Figure 2. Acquisition performance and probe trial results (mean± SEM). (A) RMANOVA for swim 
distance detected a significant within subjects effect of time [F(4,88)=22.436, p<0.001] and a significant time by 
genotype interaction [F(4.88)=2.451, p=0.012]; the between subjects effect of genotype was significant also 
[F(1,22)=13.229, p<0.001].  (B) The RMANOVA for swim time noted that the within subjects effects of time 
[F(4.88)=26.706, p<0.001], the time by genotype interaction [F(4,88)=2.667, p=0.037], and the between subjects 
effect of genotype [F(1,22)=5.466, p=0.029] were significant.  N=13 mNos2-/- mice and N=11 CVN-AD mice.  (C) 
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A RMANOVA for swim distance detected that the within subjects main effect of day was not significant, but the 
effect of zone [F(3,63)=9.693, p<0.001) and the zone by genotype interaction [F3,63)=4.618, p=0.006) were 
significant.  There was a trend for the day by zone by genotype to be significant [F(3,63)=2.241, p=0.092].  No 
other within subjects interaction or the between subjects effect of genotype were significant.  (D) A similar effect 
was found with swim time where the RMANOVA only detected the zone effect [F(3,63)=11.741, p<0.001] and 
the zone by genotype interaction [F3,63)=5.790, p=0.001] to be significant.  NE=northeast, NW=northwest, 
SE=southeast, SW=southwest. One mNos2-/-  control was not tested on the probe trial day 5 due to a 
lesion.    N=12 mNos2-/- mice and N=11 CVN-AD mice; *p<0.05, mNos2-/- versus CVN-AD mice; +p<0.05, within 
genotype versus day 1 acquisition trials. 
Figure 3. T1-weighted RARE and mGRE images were acquired for 24 mice, and the mGRE was used 
to calculate quantitative susceptibility maps. Representative images from one mouse are shown in (A). The 
control group was used to calculate minimum deformation templates (MDT) (B) for T1w RARE and mGRE 
images, to produce the deformation maps (C), and MDT for quantitative susceptibility maps (D). 
Figure 4. (A) Voxel-based analysis (VBA) identified genotype differences in all three biomarkers 
(volume, T1-weigted signal, and susceptibility). Statistical t maps were thresholded using false discovery rate 
(q). Regional properties identified areas of significant differences for (B) volume; (C) T1w signal intensity 
normalized to total brain; (D) magnetic susceptibility (QSM). Local atrophy was evident in the olfactory areas, 
septum, and dentate gyrus of the hippocampus in the CVN-AD model. Manganese uptake was lower in these 
mice, with the exception for the septum/fornix. Susceptibility was increased in the olfactory areas, caudate 
putamen, and dentate gyrus of hippocampus, but decreased in the CA1, hypothalamus, entorhinal cortex, and 
subiculum. (E) VBA identified regions were used for predicting behavior, based on regions with either positive or 
negative effects for volume, T1W signal, and QSM.
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Figure 5 (A). Using volume (A), T1w (B), QSM (C), or combination of the three biomarkers (D) as 
predictors we identified significant associations between eigen regions and swim distance on day 4. For 
all contrasts, the 1st row represents the networks identified by the sparse decomposition. The 2nd row represents 
the networks identified based on a behavior supervised decomposition. Panel E shows how the correlations 
between the predicted behavior trait for each of the models applied to the full data set, and the associated 
confidence intervals. Our results suggest the integrative approach has increased value when applied to a model 
of a complex, multifactorial disease such as AD.
Figure 6: Relative to single biomarkers, the combined set of three contrasts performed in general 
better or just as well as the best predictor, in terms of the ability to predict swim distance for regions 
selected because they were a priori expected to be involved in memory or motor function, and or AD 
pathology. We note the good predictions for the parasubiculum, involved in spatial navigation.
Supplementary Material
Supplementary Table 1. Volume Differences
Supplementary Table 2. T1w signal intensity differences
Supplementary Table 3. QSM differences in CVN-AD mice relative to mNos2-/-  controls
Supplementary Figure 1. Model performance comparison based on a whole brain unbiased analysis, 
showing the root mean square error (RMSE) between the predictions and the true values for the swim 
distance produced for the 16 models.






Tables 
Table 1. Model performance comparison based on a whole brain unbiased analysis, showing the testing root 
mean square error of the predictions (RMSE); and the whole set based Pearson correlation (corr), associated 
p value, and the explained variance (adjusted R2). 
Contrast Model Test RMSE test (cm) P CORR adjR2 rank
Positive Clusters 266.94±56.84 0.005 0.55 0.27 5
Negative Clusters 259.33±57.20 0.004 0.57 0.3 3VBA Volume
Combined Clusters 261.76±58.31 0.004 0.57 0.3 4
Positive Clusters 281.76±60.80 0.022 0.47 0.18 10
Negative Clusters 273.98±54.30 0.01 0.51 0.23 7VBA T1W
Combined Clusters 272.38±57.80 0.009 0.52 0.24 6
Positive Clusters 285.55±73.88 0.036 0.43 0.15 11
Negative Clusters 280.1±69.59 0.018 0.48 0.2 9VBA QSM
Combined Clusters 290.6±50.53 0.01 0.52 0.23 12
Volume 300.7±48.89 0.021 0.47 0.18 14
T1W 344.54±41.26 0.12 0.33 0.07 15
Sparse 
Decomposition 
(SD) QSM 299.19±79.46 0.04 0.43 0.15 13
Volume 251.05±68.81 3.43E-09 0.9 0.79 2
T1W 349.01±47.33 2.64E-07 0.84 0.69 16
Supervised 
Sparse 
Decomposition 
(SD2) QSM 279±43.42 2.56E-05 0.75 0.54 8
 Multivariate 
SD2 Volume+T1w+QSM 233.08±101.78 7.14E-12 0.94 0.88 1
Table 2. To evaluate the 16 models performance, we have compared predictions with the true values for the 
measured behavior parameters (measured in cm) based on the full data set. Our Kruskall–Wallis analyses were 
followed by posthoc Tukey Kramer tests to control for the family wise error rate. Our results indicate that the 
supervised multivariate approach outperforms 12 of the other models. CI: confidence interval. VBA: voxel based 
analysis; SD2: supervised sparse decomposition.
Model1 Model2
CI1
(cm)
Difference 
(cm)
CI2
(cm) p
T1w_VBA- COMBO_SD2 23.31 133.08 242.86 3.41E-03
COMBO_SD2 JAC_SD -237.98 -128.21 -18.43 0.01
T1w_VBA+ COMBO_SD2 16.47 126.25 236.03 0.01
COMBO_SD2 JAC_VBA+ -235.78 -126.00 -16.22 0.01
T1w_VBA_COMBO COMBO_SD2 14.72 124.50 234.28 0.01
QSM_VBA_COMBO COMBO_SD2 14.72 124.50 234.28 0.01
COMBO_SD2 JAC_VBA- -231.48 -121.71 -11.93 0.01
COMBO_SD2 T1w_SD -229.15 -119.38 -9.60 0.02
COMBO_SD2 JAC_VBA_COMBO -227.65 -117.88 -8.10 0.02
COMBO_SD2 JAC_SD2 -224.15 -114.38 -4.60 0.03
COMBO_SD2 QSM_SD2 -223.57 -113.79 -4.02 0.03
COMBO_SD2 T1w_SD2 -222.03 -112.25 -2.47 0.04
Table 3. Model performance comparison based on a ROI prior initialized based analysis, showing the testing 
root mean square error of the predictions (RMSE); and the whole set based Pearson correlation (corr), 
associated p value, and the explained variance (adjusted R2). Hc: hippocampus; PaS : parasubiculum; Cent: 
caudal entorhinal cortex; fx: fornix; M1: primary motor cortex; M2: secondary motor cortex.
Contrast Model Test RMSE test (cm) P CORR adjR2 rank
volume 288.57±93.684 0.013 0.49949 0.21538 7
T1 332.1±38.627 0.0968 0.34689 0.080345 17
QSM 332.51±34.313 0.1588 0.29697 0.046743 18
Hc
combo 285.59±82.017 9.86E-05 0.71095 0.48297 6
volume 239.09±37.498 5.16E-05 0.7299 0.51152 1
T1 334.78±27.95 0.0649 0.3827 0.10766 19
QSM 283.29±90.102 0.0099 0.5158 0.23269 5
PaS
combo 253.18±65.687 1.79E-05 0.75784 0.55498 2
volume 268.77±60.513 0.0044 0.56087 0.28342 3
T1 342.14±86.897 0.1402 0.31018 0.055132 21
QSM 325.09±72.639 0.8108 0.051575 0.042674 16
CEnt
combo 322.26±108.69 0.0044 0.56051 0.283 12
volume 293.66±78.197 0.0062 0.54258 0.26232 8
T1 350.61±103.41 0.1589 0.29689 0.046694 23
QSM 339.23±69.64 0.0314 0.4401 0.15704 20
fx
combo 323.41±120.91 0.2297 0.25469 0.022363 13
volume 323.83±131.29 0.0093 0.51959 0.2368 14
T1 312.18±113.8 0.0501 0.40417 0.12532 10
QSM 360.89±94.909 0.5723 0.12131 0.030069 24
M1
combo 317.01±162.54 0.0019 0.60205 0.33348 11
volume 309.99±113.66 0.0008 0.63947 0.38205 9
T1 276.51±56.139 0.0085 0.52486 0.24254 4
QSM 342.94±87.027 0.2891 0.22565 0.0077793 22
M2
combo 324.5±136 0.0003 0.67904 0.4366 15

Supplementary Table 1 Volume Differences
 (Ctrl: mNos2-/-; Abbr: Abbreviation; p BH: corrected p value using Benjamini Hochberg procedure, Diff: difference)
A. Atrophy
Structure
Mean 
CVN-
AD 
(%)
Mean 
Ctrl
(%)
Std AD
(%)
Std 
Ctrl 
(%)
p p BH CI1 (%) CI2 (%) t Cohen d
Diff 
(%) Abbr
Hemi-
sphere
Anterior_Commisure 0.13 0.14 0.0065 0.0039 0.0000 0.0001 -0.0178 -0.0089 -6.23 -2.55 -9.24 ac Right
Anterior_Commisure 0.14 0.15 0.0081 0.0063 0.0045 0.0183 -0.0154 -0.0032 -3.16 -1.29 -6.31 ac Left
Basal Lateral Amygdala 0.14 0.14 0.0089 0.0067 0.0067 0.0252 -0.0161 -0.0029 -2.99 -1.22 -6.58 BLA Left
Basal Lateral Amygdala 0.15 0.16 0.0073 0.0086 0.0061 0.0232 -0.0168 -0.0032 -3.04 -1.24 -6.40 BLA Right
Bed_Nucleus_of_the_Stria_Te
rminalis 0.09 0.09 0.0037 0.0033 0.0000 0.0002 -0.0110 -0.0051 -5.68 -2.33 -8.55 BNst Left
Bed_Nucleus_of_the_Stria_Te
rminalis 0.08 0.09 0.0073 0.0036 0.0043 0.0177 -0.0120 -0.0025 -3.18 -1.30 -7.98 BNst Right
Cerebral_Peduncle 0.19 0.21 0.0073 0.0091 0.0001 0.0008 -0.0237 -0.0095 -4.84 -1.98 -7.93 cp Right
Cerebral_Peduncle 0.21 0.22 0.0042 0.0078 0.0002 0.0016 -0.0171 -0.0062 -4.42 -1.81 -5.28 cp Left
Deep_Mesencephalic_Nuclei 0.25 0.27 0.0168 0.0085 0.0001 0.0009 -0.0363 -0.0143 -4.76 -1.95 -9.22 DpMe Left
Dorsal_Tegmentum 0.18 0.2 0.0079 0.0050 0.0000 0.0000 -0.0239 -0.0129 -6.95 -2.84 -9.39 NA Right
Dorsal_Tegmentum 0.18 0.2 0.0064 0.0053 0.0001 0.0007 -0.0165 -0.0067 -4.87 -1.99 -5.92 NA Left
Fastigial_Medial_Dorsolateral_
Nucleus_of_Cerebellum 0.01 0.01 0.0011 0.0008 0.0119 0.0376 -0.0018 -0.0002 -2.74 -1.12 -10.10 FasDL Left
Fastigial_Medial_Dorsolateral_
Nucleus_of_Cerebellum 0.01 0.01 0.0009 0.0007 0.0116 0.0372 -0.0016 -0.0002 -2.75 -1.13 -8.64 FasDL Right
Fimbria 0.23 0.25 0.0100 0.0107 0.0056 0.0221 -0.0219 -0.0042 -3.07 -1.26 -5.32 fi Left
Fornix 0.04 0.05 0.0024 0.0029 0.0000 0.0000 -0.0099 -0.0054 -7.05 -2.89 -15.30 fx Left
Fornix 0.05 0.05 0.0017 0.0025 0.0000 0.0000 -0.0088 -0.0051 -7.88 -3.23 -12.80 fx Right
Hypothalamus 1.08 1.24 0.0468 0.0835 0.0000 0.0003 -0.2100 -0.0928 -5.34 -2.19 -12.30 Hyp Right
Hypothalamus 1.07 1.18 0.0386 0.0442 0.0000 0.0000 -0.1460 -0.0753 -6.48 -2.66 -9.42 Hyp Left
Internal_Capsule 0.41 0.44 0.0132 0.0158 0.0006 0.0040 -0.0365 -0.0116 -4.00 -1.64 -5.47 ic Left
Internal_Capsule 0.39 0.41 0.0147 0.0200 0.0071 0.0259 -0.0367 -0.0065 -2.97 -1.22 -5.28 ic Right
Interpeduncular_Nucleus 0.03 0.03 0.0025 0.0022 0.0186 0.0509 -0.0044 -0.0004 -2.54 -1.04 -7.94 Iped Right
Lateral_Olfactory_Tract 0.16 0.18 0.0091 0.0291 0.0099 0.0329 -0.0449 -0.0069 -2.82 -1.16 -14.00 lo Right
Mamillothalamic_Tract 0.01 0.01 0.0013 0.0012 0.0074 0.0265 -0.0025 -0.0004 -2.95 -1.21 -10.30 mt Right
Optic_Tracts 0.25 0.27 0.0181 0.0257 0.0095 0.0324 -0.0455 -0.0071 -2.84 -1.17 -9.58 ot Left
Optic_Tracts 0.26 0.27 0.0151 0.0178 0.0152 0.0433 -0.0321 -0.0038 -2.63 -1.08 -6.56 ot Right
Periaquaductal_Grey 0.51 0.53 0.0234 0.0122 0.0196 0.0521 -0.0342 -0.0033 -2.52 -1.03 -3.54 PAG Right
Piriform_Cortex 5.06 5.54 0.2300 0.2040 0.0000 0.0003 -0.6600 -0.2920 -5.37 -2.20 -8.60 Pir Right
Piriform_Cortex 5.13 5.5 0.2140 0.2390 0.0007 0.0047 -0.5600 -0.1730 -3.92 -1.61 -6.66 Pir Left
Pontine_Reticular_Nucleus 0.61 0.65 0.0310 0.0283 0.0124 0.0385 -0.0581 -0.0079 -2.72 -1.12 -5.10 PnC Left
Pontine_Reticular_Nucleus 0.56 0.59 0.0174 0.0133 0.0001 0.0009 -0.0426 -0.0167 -4.74 -1.94 -5.03 PnC Right
PosteriorDorsal_Paraventricul
arMedialParvicellular_Posterio
r_LateralHypothalamus
0.12 0.12 0.0066 0.0056 0.0054 0.0216 -0.0128 -0.0025 -3.09 -1.26 -6.19 PHD_LatHy Right
PosteriorDorsal_Paraventricul
arMedialParvicellular_Posterio
r_LateralHypothalamus
0.11 0.12 0.0040 0.0058 0.0040 0.0165 -0.0110 -0.0024 -3.22 -1.32 -5.73 PHD_LatHy Left
Retro_Rubral_Field 0.04 0.05 0.0018 0.0023 0.0125 0.0385 -0.0041 -0.0006 -2.72 -1.12 -5.14 RR Left
Rostral_Linear_Nucleus 0.03 0.04 0.0037 0.0026 0.0172 0.0472 -0.0060 -0.0007 -2.58 -1.05 -9.07 RI Right
Stria_Terminalis 0.09 0.1 0.0036 0.0041 0.0001 0.0012 -0.0106 -0.0040 -4.60 -1.89 -7.19 st Left
Striatum 2.2 2.28 0.0720 0.0827 0.0203 0.0534 -0.1460 -0.0136 -2.50 -1.03 -3.50 Cpu Left
Substantia_Nigra 0.11 0.11 0.0055 0.0050 0.0137 0.0408 -0.0102 -0.0013 -2.68 -1.10 -5.18 SN Right
Subthalamic_Nucleus 0.05 0.05 0.0018 0.0019 0.0000 0.0001 -0.0064 -0.0032 -6.25 -2.56 -9.34 Sthal Left
Subthalamic_Nucleus 0.05 0.05 0.0034 0.0030 0.0039 0.0164 -0.0070 -0.0015 -3.22 -1.32 -8.32 Sthal Right
Superior_Cerebellar_Peduncle 0.09 0.1 0.0043 0.0054 0.0002 0.0016 -0.0131 -0.0047 -4.41 -1.81 -8.88 scp Right
Superior_Cerebellar_Peduncle 0.1 0.1 0.0057 0.0047 0.0062 0.0233 -0.0108 -0.0020 -3.03 -1.24 -6.27 scp Left
Superior_Colliculus 1.06 1.12 0.0464 0.0362 0.0021 0.0101 -0.0937 -0.0238 -3.49 -1.43 -5.27 SC Right
Superior_Colliculus 1.04 1.09 0.0412 0.0270 0.0009 0.0053 -0.0828 -0.0247 -3.84 -1.57 -4.93 SC Left
Tegmental_Nucleus 0 0 0.0005 0.0004 0.0142 0.0411 -0.0008 -0.0001 -2.66 -1.09 -9.96 Tg Right
Thalamus_Rest 1.05 1.1 0.0371 0.0266 0.0027 0.0128 -0.0710 -0.0170 -3.38 -1.38 -4.02 NA Right
Thalamus_Rest 1.03 1.07 0.0334 0.0226 0.0022 0.0106 -0.0635 -0.0159 -3.46 -1.42 -3.73 NA Left
Zona_Incerta 0.22 0.23 0.0091 0.0082 0.0009 0.0053 -0.0209 -0.0063 -3.84 -1.57 -5.87 ZI Right
Zona_Incerta 0.24 0.25 0.0094 0.0072 0.0029 0.0133 -0.0185 -0.0044 -3.35 -1.37 -4.55 ZI Left
B. Hypertrophy
(Ctrl: mNos2-/-; Abbr: Abbreviation; p BH: corrected p value using Benjamini Hochberg procedure, Diff: difference)
Structure
Mean 
CVN-AD 
(%)
Mean 
Ctrl
(%)
Std 
AD
(%)
Std 
Ctrl
*%)
p p BH CI1(%)
CI2
(%) t
Cohen 
d
Diff
(%) Abbr
Hemi-
sphere
Caudomedial_Entorhinal_C
ortex 0.599 0.559 0.021 0.015 0.0000 0.0002 0.025 0.055 5.507 2.253 7.175 CEnt Left
Caudomedial_Entorhinal_C
ortex 0.573 0.534 0.017 0.019 0.0000 0.0004 0.023 0.054 5.205 2.133 7.267 CEnt Right
Cerebellar_Cortex 4.985 4.644 0.105 0.154 0.0000 0.0001 0.228 0.455 6.232 2.557 7.352
1Cb_to_10C
b Left
Cerebellar_Cortex 4.85 4.458 0.108 0.117 0.0000 0.0000 0.296 0.488 8.464 3.468 8.792
1Cb_to_10C
b Right
Cerebellar_White_Matter 1.183 1.127 0.021 0.032 0.0001 0.0007 0.032 0.079 4.908 2.014 4.903 cbw Left
Cerebellar_White_Matter 1.215 1.151 0.022 0.03 0.0000 0.0001 0.041 0.087 5.863 2.404 5.566 cbw Right
Cingulate_Cortex_Area_24
a 0.195 0.18 0.018 0.01 0.0147 0.0422 0.003 0.027 2.648 1.082 8.523 A24a Right
Cingulate_Cortex_Area_24
b 0.165 0.15 0.014 0.006 0.0015 0.0084 0.006 0.023 3.617 1.477 9.928 A24b Right
Cingulate_Cortex_Area_24
b_prime 0.046 0.042 0.003 0.003 0.0013 0.0075 0.002 0.006 3.685 1.509 9.231 A24bPrime Left
Cingulate_Cortex_Area_24
b_prime 0.055 0.047 0.005 0.002 0.0000 0.0003 0.005 0.01 5.391 2.202 15.562 A24bPrime Right
Cingulate_Cortex_Area_29
a 0.055 0.049 0.005 0.003 0.0031 0.0139 0.002 0.01 3.329 1.362 12.109 A29a Left
Cingulate_Cortex_Area_29c 0.14 0.13 0.013 0.006 0.0165 0.0457 0.002 0.019 2.597 1.061 7.921 A29c Right
Cingulate_Cortex_Area_30 0.292 0.269 0.009 0.009 0.0000 0.0001 0.015 0.03 6.31 2.585 8.470 A30 Left
Cingulate_Cortex_Area_30 0.298 0.272 0.01 0.013 0.0000 0.0003 0.016 0.036 5.354 2.196 9.542 A30 Right
Cingulate_Cortex_Area_32 0.22 0.2 0.013 0.011 0.0009 0.0053 0.009 0.029 3.845 1.574 9.514 A32 Right
Claustrum 0.032 0.028 0.003 0.002 0.0034 0.0149 0.001 0.006 3.281 1.342 12.442 Cl Right
Dorsal_Claustrum 0.013 0.011 0.001 0.001 0.0015 0.0084 0.001 0.002 3.617 1.481 12.247 DCl Right
Dorsal_Claustrum 0.017 0.015 0.002 0.002 0.0018 0.0094 0.001 0.004 3.547 1.452 16.962 DCl Left
Dorsal_Tenia_Tecta 0.051 0.046 0.004 0.003 0.0038 0.0161 0.002 0.008 3.239 1.325 10.965 DTT Left
Dorsal_Tenia_Tecta 0.056 0.049 0.005 0.006 0.0080 0.0283 0.002 0.011 2.917 1.195 13.324 DTT Right
Ectorhinal_Cortex 0.263 0.253 0.009 0.01 0.0162 0.0454 0.002 0.018 2.604 1.067 3.925 Ect Right
Ectorhinal_Cortex 0.286 0.261 0.007 0.015 0.0000 0.0005 0.015 0.035 5.121 2.103 9.554 Ect Left
Frontal_Association_Cortex 0.88 0.83 0.049 0.038 0.0103 0.0334 0.013 0.086 2.805 1.148 5.986 FrA Right
Frontal_Cortex_Area_3 0.096 0.09 0.006 0.004 0.0068 0.0253 0.002 0.01 2.984 1.221 6.723 Fr3 Left
Frontal_Cortex_Area_3 0.102 0.092 0.007 0.004 0.0002 0.0016 0.005 0.015 4.402 1.799 10.899 Fr3 Right
Insular_Cortex 0.705 0.676 0.036 0.019 0.0189 0.0511 0.005 0.053 2.535 1.036 4.316 Ins Right
Insular_Cortex 0.797 0.738 0.027 0.03 0.0001 0.0006 0.034 0.083 4.984 2.043 7.980 Ins Left
Lateral_Orbital_Cortex 0.365 0.327 0.027 0.011 0.0001 0.0011 0.021 0.055 4.625 1.889 11.681 LO Right
Latero_Posterior_Nuclei_of
_Thalamus 0.018 0.016 0.002 0.001 0.0157 0.0442 0 0.003 2.62 1.071 9.566 LP Left
Medial_Entorhinal_Cortex 0.086 0.079 0.008 0.005 0.0101 0.0332 0.002 0.013 2.816 1.152 9.397 MEnt Right
Medial_Entorhinal_Cortex 0.089 0.08 0.008 0.004 0.0019 0.0096 0.003 0.013 3.523 1.44 10.456 MEnt Left
Medial_Geniculate_Nucleus 0.043 0.041 0.002 0.002 0.0017 0.0092 0.001 0.004 3.564 1.461 6.308 MGN Left
Medial_Orbital_Cortex 0.14 0.121 0.01 0.008 0.0001 0.0006 0.011 0.026 5.017 2.054 15.139 MO Left
Medial_Orbital_Cortex 0.151 0.126 0.007 0.007 0.0000 0.0000 0.019 0.031 8.831 3.618 19.789 MO Right
Medial_Parietal_Association
_Cortex 0.035 0.032 0.003 0.002 0.0134 0.0405 0.001 0.005 2.69 1.1 7.989 MPtA Right
Medial_Parietal_Association
_Cortex 0.036 0.033 0.003 0.002 0.0133 0.0405 0.001 0.005 2.693 1.101 8.914 MPtA Left
Parasubiculum 0.106 0.087 0.006 0.005 0.0000 0.0000 0.014 0.023 8.611 3.526 21.189 PaS Left
Parasubiculum 0.125 0.101 0.007 0.008 0.0000 0.0000 0.017 0.029 7.622 3.125 22.766 PaS Right
Perirhinal_Cortex 0.224 0.214 0.006 0.011 0.0135 0.0405 0.002 0.017 2.686 1.102 4.523 PRh Left
Postsubiculum 0.096 0.09 0.004 0.005 0.0033 0.0147 0.002 0.01 3.294 1.35 6.535 Post Left
Postsubiculum 0.096 0.086 0.008 0.007 0.0056 0.0221 0.003 0.016 3.068 1.257 10.793 Post Right
Presubiculum 0.017 0.015 0.001 0.001 0.0006 0.0038 0.001 0.003 4.028 1.652 13.215 PrS Right
Presubiculum 0.019 0.016 0.002 0.001 0.0002 0.0016 0.001 0.004 4.412 1.805 16.854 PrS Left
Primary_Auditory_Cortex 0.164 0.155 0.005 0.006 0.0008 0.0052 0.004 0.013 3.87 1.587 5.392 Au1 Right
Primary_Auditory_Cortex 0.176 0.165 0.005 0.007 0.0003 0.0020 0.006 0.017 4.298 1.763 6.764 Au1 Left
Primary_Motor_Cortex 0.71 0.672 0.03 0.021 0.0017 0.0089 0.016 0.059 3.584 1.466 5.583 M1 Right
Primary_Somatosensory_C
ortex 0.084 0.079 0.005 0.003 0.0038 0.0161 0.002 0.009 3.238 1.325 6.681 S1 Left
Primary_Somatosensory_C
ortex 0.094 0.087 0.006 0.005 0.0058 0.0224 0.002 0.012 3.057 1.251 8.361 S1 Right
Primary_Somatosensory_C
ortex_Barrel_Field 0.883 0.839 0.033 0.025 0.0015 0.0084 0.018 0.068 3.624 1.483 5.130 S1BF Left
Primary_Somatosensory_C
ortex_Dysgranular_Zone 0.135 0.126 0.01 0.003 0.0072 0.0259 0.003 0.014 2.965 1.211 6.732 S1DZ Right
Primary_Somatosensory_C
ortex_Jaw_Region 0.283 0.263 0.012 0.01 0.0002 0.0012 0.011 0.03 4.568 1.87 7.818 S1J Right
Primary_Somatosensory_C
ortex_Jaw_Region 0.305 0.279 0.017 0.012 0.0003 0.0019 0.014 0.039 4.326 1.77 9.350 S1J Left
Primary_Somatosensory_C
ortex_Upper_Lip_Region 0.416 0.399 0.015 0.014 0.0086 0.0297 0.005 0.03 2.887 1.182 4.348 S1ULp Right
Primary_Somatosensory_C
ortex_Upper_Lip_Region 0.432 0.391 0.018 0.012 0.0000 0.0000 0.028 0.054 6.497 2.658 10.512 S1ULp Left
Primary_Somatosensory_C
ortexForelimb_Region 0.328 0.304 0.015 0.009 0.0001 0.0008 0.014 0.035 4.79 1.959 7.996 S1FL Right
Primary_Visual_Cortex_Bin
ocular_Area 0.192 0.178 0.016 0.011 0.0213 0.0553 0.002 0.025 2.48 1.015 7.700 V1B Left
Primary_Visual_Cortex_Bin
ocular_Area 0.196 0.182 0.006 0.007 0.0000 0.0004 0.009 0.02 5.269 2.159 8.081 V1B Right
Primary_Visual_Cortex_Mo
nocular_Area 0.451 0.429 0.024 0.011 0.0083 0.0292 0.006 0.038 2.898 1.184 5.115 V1M Right
Primary_Visual_Cortex_Mo
nocular_Area 0.415 0.391 0.026 0.018 0.0140 0.0411 0.005 0.043 2.668 1.092 6.214 V1M Left
Pyramidal_Tract 0.1 0.089 0.012 0.008 0.0097 0.0328 0.003 0.019 2.83 1.158 12.458 py Right
Pyramidal_Tract 0.109 0.095 0.014 0.011 0.0141 0.0411 0.003 0.024 2.665 1.091 14.023 py Left
Secondary_Auditory_Cortex
_Dorsal_Part 0.191 0.183 0.008 0.008 0.0204 0.0534 0.001 0.015 2.5 1.024 4.382 AuD Right
Secondary_Auditory_Cortex
_Dorsal_Part 0.198 0.188 0.01 0.007 0.0095 0.0324 0.003 0.017 2.84 1.162 5.229 AuD Left
Secondary_Auditory_Cortex
_Ventral_Part 0.201 0.193 0.004 0.009 0.0122 0.0382 0.002 0.014 2.732 1.122 4.150 AuV Left
Secondary_Motor_Cortex 0.636 0.609 0.027 0.025 0.0194 0.0521 0.005 0.049 2.521 1.032 4.386 M2 Left
Secondary_Motor_Cortex 0.68 0.63 0.033 0.019 0.0001 0.0010 0.028 0.073 4.698 1.921 8.052 M2 Right
Secondary_Somatosensory
_Cortex 0.68 0.632 0.02 0.018 0.0000 0.0001 0.032 0.064 6.091 2.494 7.575 S2 Right
Secondary_Somatosensory
_Cortex 0.646 0.58 0.025 0.024 0.0000 0.0000 0.045 0.087 6.56 2.687 11.382 S2 Left
Secondary_Visual_CortexL
ateral_Area 0.27 0.253 0.012 0.008 0.0004 0.0030 0.008 0.025 4.125 1.688 6.489 V2L Right
Secondary_Visual_CortexL
ateral_Area 0.277 0.252 0.013 0.014 0.0001 0.0012 0.014 0.036 4.585 1.879 9.923 V2L Left
Temporal_Association_Cort
ex 0.326 0.304 0.013 0.008 0.0000 0.0004 0.013 0.031 5.141 2.102 7.304 TeA Right
Temporal_Association_Cort
ex 0.343 0.311 0.011 0.014 0.0000 0.0001 0.021 0.043 6.158 2.525 10.299 TeA Left
Ventral_Intermediate_Entor
hinal_Cortex 0.148 0.135 0.01 0.008 0.0020 0.0097 0.005 0.02 3.508 1.436 9.346 VIEnt Right
Ventral_Orbital_Cortex 0.15 0.139 0.012 0.007 0.0103 0.0334 0.003 0.02 2.805 1.147 8.201 VO Left
Ventral_Orbital_Cortex 0.156 0.14 0.01 0.004 0.0000 0.0002 0.01 0.023 5.538 2.263 11.968 VO Right
Supplementary Table 2. T1w signal intensity differences
(Ctrl: mNos2-/-; Abbr: Abbreviation; p BH: corrected p value using Benjamini Hochberg procedure)
Structure
Mean 
CVN-AD
(AU)
Mean 
Ctrl
(AU)
Std AD
(AU)
Std 
Ctrl
(AU)
p p BH CI1(AU)
CI2
(AU) t
Cohen 
d
Differ
ence
(%)
Abbr Hemisphere
Accumbens 12505.47 12817.85 179.52 252.83 0.0024 0.0444 -501.43 -123.32 -3.43 -1.40 -2.44 Acb Left
Caudomedial_Entorhinal_C
ortex 10441.80 10842.40 222.90 199.30 0.0001 0.0411 -579.32 -221.88 -4.65 -1.90 -3.69 CEnt Right
Central_Gray 11851.43 12530.45 524.97 392.64 0.0015 0.0444 -1067.76 -290.27 -3.62 -1.48 -5.42 CG Left
Cingulate_Cortex_Area_24
a 12746.11 13240.90 349.27 270.58 0.0008 0.0430 -757.19 -232.40 -3.91 -1.60 -3.74 A24a Right
Cingulate_Cortex_Area_24
a_prime 13218.88 13925.76 340.80 513.55 0.0008 0.0430 -1083.65 -330.12 -3.89 -1.59 -5.08
A24aPri
me Left
Cingulate_Cortex_Area_24
a_prime 12770.20 13512.56 276.76 580.38 0.0008 0.0430 -1139.54 -345.17 -3.88 -1.59 -5.49
A24aPri
me Right
Cingulate_Cortex_Area_24
b 13375.26 13790.90 260.77 325.50 0.0025 0.0444 -668.68 -162.61 -3.41 -1.40 -3.01 A24b Left
Cingulate_Cortex_Area_29
a 12914.48 13558.58 332.18 515.22 0.0018 0.0444 -1019.23 -268.98 -3.56 -1.46 -4.75 A29a Left
Cochlear_Nucleus 10548.93 11258.91 511.75 448.31 0.0015 0.0444 -1116.25 -303.70 -3.62 -1.48 -6.31 CoN Left
Facial_Nerve 11288.89 11810.32 374.75 323.40 0.0014 0.0444 -816.82 -226.03 -3.66 -1.50 -4.42 n7 Left
Fastigial_Medial_Dorsolater
al_Nucleus_of_Cerebellum 12012.35 12602.01 423.45 394.41 0.0019 0.0444 -936.19 -243.14 -3.53 -1.45 -4.68 FasDL Left
Fornix 12004.69 11714.81 207.74 204.16 0.0024 0.0444 115.03 464.73 3.44 1.41 2.47 fx Left
Hippocampus 12742.53 13080.92 293.76 188.05 0.0025 0.0444 -543.91 -132.87 -3.41 -1.40 -2.59 Hc Right
Inferior_Cerebellar_Peduncl
e 8942.66 9442.07 397.22 221.96 0.0008 0.0430 -766.18 -232.63 -3.88 -1.59 -5.29
icp_oc_t
z Left
Middle_Cerebellar_Peduncl
e 10080.60 10565.31 437.50 254.25 0.0027 0.0444 -781.78 -187.64 -3.38 -1.39 -4.59 mcp Left
Parabrachial 
Koelliker_Fuse_Nucleus 12237.93 12909.24 439.72 417.95 0.0009 0.0430 -1034.93 -307.69 -3.83 -1.57 -5.20 KF Left
Parasubiculum 12023.36 12546.10 478.83 271.04 0.0028 0.0448 -845.47 -200.02 -3.36 -1.38 -4.17 PaS Right
Pedunculotegmental 
_Supratrigemnial_Nuclei 12977.70 13590.20 510.47 370.33 0.0026 0.0444 -985.99 -239.01 -3.40 -1.39 -4.51 Su5 Left
Primary_Somatosensory_C
ortex_Jaw_Region 12882.77 13186.41 183.84 227.39 0.0018 0.0444 -480.97 -126.30 -3.55 -1.45 -2.30 S1J Right
Ventral_Spinocerebellar_Tr
act 11587.32 12022.76 336.78 225.00 0.0010 0.0430 -674.49 -196.38 -3.78 -1.55 -3.62 vsc Left
Vestibulocochlear_Nerve 9880.86 10520.64 413.62 304.92 0.0003 0.0419 -944.31 -335.25 -4.36 -1.78 -6.08 n8 Left
Supplementary Table 3. QSM differences in CVN-AD mice relative to mNos2-/-  controls
(Ctrl: mNos2-/-; Abbr: Abbreviation; p BH: corrected p value using Benjamini Hochberg procedure)
Structure
Mean 
CVN-AD
(ppm)
Mean 
Ctrl
(ppm)
Std AD
(ppm)
Std 
Ctrl
(ppm)
p p BH CI1(ppm)
CI2
(ppm) t
Cohen 
d
Difference
(%) Abbr
Hemi-
sphere
Fimbria 0.0005 -0.0034 0.0019 0.0020 0.0001 0.0054 0.0022 0.0055 4.82 1.97 -113.73 fi Left
Hippocampus 0.0000 -0.0015 0.0006 0.0011 0.0009 0.0219 0.0007 0.0023 3.85 1.58 -97.27 Hc Left
Insular_Cortex -0.0006 -0.0010 0.0003 0.0003 0.0026 0.0501 0.0002 0.0007 3.40 1.39 -42.38 Ins Left
Interposed_Nucleus_of_Cer
ebellum 0.0030 0.0077 0.0042 0.0024 0.0022 0.0466 -0.0076 -0.0019 -3.47 -1.42 -61.70 Int Right
Lateral_Geniculate_Nucleus 0.0013 -0.0049 0.0025 0.0032 0.0000 0.0041 0.0037 0.0087 5.14 2.11 -127.38 LGN Left
Medial_Orbital_Cortex -0.0017 -0.0059 0.0014 0.0020 0.0000 0.0022 0.0027 0.0057 5.87 2.41 -71.20 MO Left
Medial_Orbital_Cortex -0.0012 -0.0044 0.0018 0.0022 0.0009 0.0219 0.0015 0.0050 3.85 1.58 -72.49 MO Right
PosteriorDorsal_Paraventric
ularMedialParvicellular_Post
erior_LateralHypothalamus 0.0003 0.0031 0.0013 0.0016 0.0001 0.0068 -0.0040 -0.0015 -4.59 -1.88 -89.10
PHD 
_Lat
Hy Left
Pretectal_Nucleus 0.0014 -0.0059 0.0058 0.0035 0.0009 0.0219 0.0034 0.0114 3.82 1.57 -124.15 APT Right
Primary_Somatosensory_Co
rtex -0.0002 -0.0027 0.0013 0.0016 0.0004 0.0169 0.0013 0.0037 4.16 1.70 -92.57 S1 Right
Red_Nucleus_Magnocellular -0.0041 -0.0079 0.0023 0.0014 0.0000 0.0041 0.0022 0.0054 5.03 2.06 -48.17 RMC Left
Ventral_Hippocampal_Com
missure 0.0003 -0.0054 0.0043 0.0038 0.0023 0.0466 0.0023 0.0091 3.46 1.42 -106.18 vhc Right
Ventral_Thalamic_Nuclei -0.0003 -0.0030 0.0019 0.0012 0.0005 0.0179 0.0013 0.0040 4.09 1.68 -88.78 VT Right
Ventral_Thalamic_Nuclei -0.0003 -0.0025 0.0018 0.0009 0.0006 0.0206 0.0011 0.0034 3.99 1.63 -87.13 VT Left
Periaquaductal_Grey 0.0030 0.0002 0.0016 0.0019 0.0008 0.0219 0.0013 0.0043 3.87 1.58 1475.14 PAG Left
